52093-13-7

Basic information

• Product Name: 2-CHLORO-N''-(CHLOROACETYL)BENZOHYDRAZIDE
• Synonyms: 2-chloro-N'-(2-chloroacetyl)benzohydrazide
• CAS NO: 52093-13-7
• Molecular Formula: C₉H₈Cl₂N₂O₂
• Molecular Weight: 247.07802
• Mol File: 52093-13-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 489.4°Cat760mmHg
• Flash Point: 249.8°C
• Appearance: /
• Density: 1.407g/cm³
• CAS DataBase Reference: 2-CHLORO-N''-(CHLOROACETYL)BENZOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N''-(CHLOROACETYL)BENZOHYDRAZIDE(52093-13-7)
• EPA Substance Registry System: 2-CHLORO-N''-(CHLOROACETYL)BENZOHYDRAZIDE(52093-13-7)

Safety Data

• Hazardous Substances Data: 52093-13-7(Hazardous Substances Data)

Upstream product

• 7335-25-3 ethyl 2-chlorobenzoate 
• 79-04-9 chloroacetyl chloride 
• 5814-05-1 2-chlorobenzoylhydrazide 
• 118-91-2 ortho-chlorobenzoic acid 

Downstream Products

• 24023-72-1 2‐(chloromethyl)‐5‐(2‐chlorophenyl)‐1,3,4‐oxadiazole 

Relevant articles and documents

Synthesis and biological evaluation of honokiol derivatives bearing 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3h)-ones as potential viral entry inhibitors against sars-cov-2

The 2019 coronavirus disease (COVID-19) caused by SARS-CoV-2 virus infection has posed a serious danger to global health and the economy. However, SARS-CoV-2 medications that are specific and effective are still being developed. Honokiol is a bioactive component from Magnoliae officinalis Cortex with damp-drying effect. To develop new potent antiviral molecules, a series of novel honokiol analogues were synthesized by introducing various 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3H)-ones to its molecule. In a SARS-CoV-2 pseudovirus model, all honokiol derivatives were examined for their antiviral entry activities. As a result, 6a and 6p demonstrated antiviral entry effect with IC50 values of 29.23 and 9.82 μM, respectively. However, the parental honokiol had a very weak antiviral activity with an IC50 value more than 50 μM. A biolayer interfero-metry (BLI) binding assay and molecular docking study revealed that 6p binds to human ACE2 protein with higher binding affinity and lower binding energy than the parental honokiol. A competitive ELISA assay confirmed the inhibitory effect of 6p on SARS-CoV-2 spike RBD’s binding with ACE2. Importantly, 6a and 6p (TC50 > 100 μM) also had higher biological safety for host cells than honokiol (TC50 of 48.23 μM). This research may contribute to the discovery of potential viral entrance inhibitors for the SARS-CoV-2 virus, although 6p’s antiviral efficacy needs to be validated on SARS-CoV-2 viral strains in a biosafety level 3 facility.

Design and synthesis of new norfloxacin-1,3,4-oxadiazole hybrids as antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA)

Toward the search of new antibacterial agents to control methicillin-resistant Staphylococcus aureus (MRSA), a class of new norfloxacin-1,3,4-oxadiazole hybrids were designed and synthesized. Antibacterial activities against drug-sensitive bacteria S. aureus and clinical drug resistant isolates of MRSA were evaluated. Compound 5k exhibited excellent antibacterial activities against S. aureus (MIC: 2 μg/mL) and MRSA1–3 (MIC: 0.25–1 μg/mL). The time-kill kinetics demonstrated that compound 5k had an advantage over commonly used antibiotics vancomycin in killing S. aureus and MRSA. Moreover, compound 5k could inhibit the bacteria and destroy their membranes in a short time, and showed very low cytotoxicity to NRK-52E cells. Some interesting structure-activity relationships (SARs) were also discussed. These results indicated that these norfloxacin-1,3,4-oxadiazole hybrids could be further developed into new antibacterial agents against MRSA.